Doctors call Wegovy’s new weight loss pill a game changer in the fight against obesity, but some experts are urging patients to be cautious.

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss ...

Wegovy pill, the first FDA‑approved oral GLP‑1 for weight loss, is now available via Weight Watchers Med+ from $149 per month for a limited time.

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two ...

Federal officials had warned that the new product from the online provider of weight loss drugs might be illegal. By Rebecca Robbins Hims & Hers, a major online provider of obesity medications, said ...

Consumers can currently access 43 different drugs through TrumpRx for a range of conditions. For instance, users seeking fertility drugs can get an 83% discount on Gonal F, a medication containing a ...

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy.

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe ...

Wegovy, a prescription medication designed to aid in weight loss, is now available in the United States, opening new doors for individuals managing obesity. The drug, part of a class of medications ...

A weekly injection is no longer the only way to reap the obesity management and weight loss benefits of glucagon-like peptide-1 (GLP-1) medications. One oral GLP-1 option is now approved by the U.S.

To The Contrary is available to stream on pbs.org and the free PBS App, available on iPhone, Apple TV, Android TV, Android smartphones, Amazon Fire TV, Amazon Fire Tablet, Roku, Samsung Smart TV, and ...

Glucagon-like peptide-1 (GLP-1) medications, such as Wegovy (semaglutide), have helped many people lose weight. Until recently, these options required regular injections — a potential dealbreaker for ...